Sava Infond d.o.o. Invests $1.49 Million in Stryker Co. (NYSE:SYK)

Sava Infond d.o.o. bought a new position in Stryker Co. (NYSE:SYK) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 4,150 shares of the medical technology company’s stock, valued at approximately $1,494,000.

Several other hedge funds have also added to or reduced their stakes in the business. Kohmann Bosshard Financial Services LLC bought a new position in shares of Stryker in the fourth quarter worth approximately $25,000. Dunhill Financial LLC increased its position in Stryker by 94.9% during the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 37 shares during the period. Rakuten Securities Inc. raised its holdings in Stryker by 618.2% in the 4th quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock worth $28,000 after purchasing an additional 68 shares in the last quarter. Centricity Wealth Management LLC purchased a new stake in shares of Stryker in the 4th quarter worth about $30,000. Finally, BankPlus Trust Department bought a new stake in shares of Stryker during the 4th quarter valued at about $33,000. 77.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SYK has been the subject of several research analyst reports. Stifel Nicolaus raised their price objective on shares of Stryker from $400.00 to $440.00 and gave the stock a “buy” rating in a report on Wednesday, January 29th. Needham & Company LLC restated a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Friday, March 21st. StockNews.com cut Stryker from a “buy” rating to a “hold” rating in a research note on Thursday, March 6th. Wells Fargo & Company raised their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a research report on Wednesday, January 29th. Finally, Citigroup reissued a “buy” rating and set a $450.00 price target on shares of Stryker in a research report on Wednesday, February 26th. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $421.90.

Stryker Stock Down 1.5 %

SYK opened at $367.34 on Thursday. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The firm has a 50 day moving average price of $384.74 and a 200-day moving average price of $374.29. The stock has a market capitalization of $140.17 billion, a price-to-earnings ratio of 47.34, a PEG ratio of 2.93 and a beta of 0.95.

Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same quarter in the previous year, the firm earned $3.46 earnings per share. Equities research analysts forecast that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.91%. Stryker’s dividend payout ratio (DPR) is 43.30%.

Insiders Place Their Bets

In related news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction dated Friday, January 31st. The stock was sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares in the company, valued at approximately $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the business’s stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.